The Leukemia & Lymphoma Society’s Therapy Acceleration Program (TAP) is a mission-driven venture philanthropy initiative designed. See contact routes.
The Leukemia & Lymphoma Society’s Therapy Acceleration Program (TAP) is a mission-driven venture philanthropy initiative designed to accelerate innovative blood cancer therapeutics and generate returns for the LLS Mission. TAP targets high-risk, first-in-class assets addressing unmet needs in leukemia, lymphoma, and multiple myeloma, funding novel platforms and rare blood cancers from late-stage preclinical through registrational clinical trials. The program typically provides equity or asset funding between $500,000 and $9 million per project, with individual investments reaching up to approximately $10 million, and generally co-funds trials without exceeding 50% of total costs. TAP operates as a collaborative partner rather than a traditional lead investor, offering funded companies strategic insights into blood cancer indications and the treatment landscape alongside capital. While the search results do not list specific named portfolio companies, the program explicitly supports emerging patient populations and rare blood cancer assets alongside first-in-human trials. TAP’s distinctive point of view centers on “venture philanthropy,” blending the goal of
Details on this firm come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in New York.
Investors like The Leukemia & Lymphoma Society’s Therapy Acceleration Program · Full investor directory · Investor access · Company funding database